BiotechTV - News

Episodes

Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more

October 7, 2026

Eli Lilly CEO David Ricks details the future of GLP-1 expansion, M&A strategy, and landmark Alzheimer’s trials at BiotechTV.

After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress

October 5, 2026

Insilico Medicine CEO Alex Zhavoronkov reveals how AI-driven drug discovery and clinical aging clocks are validating gerotherapeutics.

Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease

October 2, 2026

Monte Rosa's molecular glue MRT-8102 shows promising biomarker data, targeting the NLRP3 inflammasome for cardiovascular & inflammatory diseases.

From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung

September 29, 2026

TOLREMO Therapeutics targets cancer resistance with a safer CBP/p300 inhibitor. Phase 1 monotherapy data shows promise in solid tumors.

From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage

September 28, 2026

Basel's Forty51 Ventures pioneers a company-building model, providing the first ~$4M to in-license global pharma assets and build new biotechs.

From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections

September 28, 2026

Basilea leads in anti-infectives with a profitable partnership model. Growing revenues from two drugs & a promising P3 asset secure its future.

Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study

September 21, 2026

Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa hit its Phase 3 endpoint, with >30% of patients seeing major improvement.

HCW 2026: BlossomHill IPO'd last month to tackle precision oncology, with a Scientific Founder / CEO who already has a hall of fame record in the space - Jean Cui walks us through her programs

September 16, 2026

BlossomHill Therapeutics CEO Jean Cui discusses their recent IPO and pipeline tackling EGFR & pan-KRAS resistance with novel drug designs.

HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic."

September 15, 2026

GenFit's blood test is key to unlocking the MASH market, enabling patient identification and monitoring for newly approved therapies.

HCW 2026: With an in-human proof of concept in hand from a rare condition, Prime Medicine is ready to go broader in new indications

September 15, 2026

Prime Medicine leverages in-human proof of concept from a rare disease to expand its versatile gene editing platform into broader indications.

HCW 26: H.C. Wainwright Senior Biotechnology Analyst Mitchell Kapoor touches on current biotech sentiment, the cardiovascular space, in vivo CAR-T, and a pancreatic study to watch

September 14, 2026

Biotech analyst Mitchell Kapoor discusses the small-cap rally, a pivot to validated targets in cardiology, and the rise of in vivo CAR-T.

HCW 2026: H.C. Wainwright & Co.'s Vice Chair and President of Capital Markets Richard Gormley believes the elements (M&A, IPOs opening up, other financing opportunities) are still ripe for biotech

September 14, 2026

Biotech is booming. H.C. Wainwright's Richard Gormley credits record M&A, a reopened IPO market, and strong capital flow for the sector's rally.

HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab

September 14, 2026

Innate Pharma secures a key deal with Sobi for lacutamab, anticipates a major readout for monalizumab, and advances a differentiated ADC.

HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better

September 14, 2026

Alto Neuro combines proven depression drug pramipexole with an antiemetic, aiming to unlock its high efficacy by solving its key tolerability issue.

UC Berkeley's Gokul Upadhyayula and Eric Betzig are building AI to interpret detailed movies of living cells captured by their MOSAIC microscope

September 8, 2026

UC Berkeley scientists are building vision AI to interpret 5D movies of living cells, aiming to break research bottlenecks and transform drug discovery.

Bay Area based Moonwalk Biosciences announced a $70M series B today to advance its adipose-targeted RNAi therapies for obesity and cardiometabolic diseases

September 8, 2026

Moonwalk Biosciences raises $70M Series B for its adipose-targeted RNAi obesity therapy, aiming for long-acting doses that preserve muscle.

Pareto Securities Healthcare Conference: Sedana Medical's inhaled sedative drug/device combo is currently in front of FDA - they hope to change the ICU with it

September 2, 2026

Sedana Medical's inhaled sedative is before the FDA, aiming to disrupt ICU care with faster recovery, less organ strain, and shorter stays.

Pareto Securities Healthcare Conference: Hansa Biopharma has a December 16 PDUFA data with FDA for its IgG depleting therapy that hopes to make more patients eligible for kidney transplant

September 2, 2026

Hansa Biopharma's Imlifidase, an IgG-depleting drug, awaits a Dec 19 FDA decision for kidney transplants and plans a US secondary listing.

A focus on cutting edge science and a busy year of presentations and partnerships has made Circio not just one of the fastest growing biotech companies in the Nordic region, but in all of Europe

September 1, 2026

Bio Arctic advances Alzheimer's care with a new Lequimbi version, progresses a Parkinson's drug, & expands its brain-delivery platform.

Remix Therapeutics announced earlier this summer plans to go public via a reverse merger - it's on the back of clinical data that was presented for its RNA modulator at ASCO

August 26, 2026

Remix Therapeutics targets 'undruggable' oncogenes via RNA modulation, showing a 43% response rate in a rare cancer ahead of a reverse merger.

LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants

August 6, 2026

LifeMine Therapeutics raises $263M, backed by Gates & Bezos, to advance a safer organ transplant drug that avoids tacrolimus's severe toxicity.

U.S. Science Summit: Biotech veteran Harvey Berger presents an overview of the history of Kendall Square and what is at stake to keep it a leader in life sciences

July 27, 2026

Biotech veteran Harvey Berger charts Kendall Square's rise from industrial district to a life sciences hub, warning it must innovate to stay ahead.

U.S. Science Summit: "Who will shape the future of Bio?" with Recursion President & CEO Najat Khan

July 23, 2026

Recursion CEO Najat Khan on using AI to decode biology, the need for systems-thinking leaders, and building public trust in biotech.

ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

May 31, 2026

Eikon CEO Roger Perlmutter details their microscopy-driven platform, clinical strategy for in-licensed assets, and the rise of Chinese biotech.

London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors

May 5, 2026

Cytospire Therapeutics secures $83M Series A to advance its novel pan-gamma delta T-cell engagers for solid tumors, led by an EGFR program.

Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process

April 22, 2026

Replimune's Chairman discusses the controversial FDA rejection of their melanoma drug and the company's FOIA request for transparency.

Bay Area based Epia Neuro exited stealth earlier this month with the goal of developing a device implanted in the skull that could act as an interface to a glove to helps stroke survivors regain grip

April 21, 2026

Epia Neuro is developing a skull implant & motorized glove to restore grip for stroke survivors, using AI to translate intent into action.

Peter Hotez discusses tropical disease, the importance of science communication, career advice for young scientists, and more

April 21, 2026

Dr. Peter Hotez discusses combating misinformation, funding tropical disease vaccines, and strategic career advice for young scientists.

Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar

April 20, 2026

Nektar's IL-2 drug Respeg shows promising 52-week data in alopecia, surpassing standard-of-care with a superior safety profile.

10x Genomics today is announcing Atera, its new in situ spatial transcriptomics platform

April 19, 2026

10x Genomics launches Atera, a spatial biology platform to map the full transcriptome, providing a holistic view of biology to fuel AI discovery.

Raymond James Biotech Innovation Symposium: Biotech analyst Tiago Fauth shares his read on the mood of investors and discusses companies he covers

April 14, 2026

Raymond James analyst Tiago Fauth discusses improving biotech investor sentiment and key value drivers for Praxis, InsMed, Ionis, and PTC.

Raymond James Biotech Innovation Symposium: Eupraxia has a novel extended release platform for - with data already out and more on the way later this year, Eosinophilic Esophagitis has been a good PoC

April 14, 2026

Eupraxia Pharma's extended-release platform delivers hyper-local, stable drug levels for up to a year, with promising EOE data out now.

Alloy Therapeutics announced a deal with Biogen today to help them discover antisense therapeutics using Alloy's ASO platform. Alloy Founder & CEO Errik Anderson fills us in at the company's R&D Day.

April 8, 2026

Alloy Therapeutics partners with Biogen on its ASO platform, highlighting its model of high-quality drug discovery services and AI integration.

The new CEO of Stoke Therapeutics, Ian Smith, discusses Stoke Therapeutics' Dravet syndrome therapy, which caught much attention after publishing phase 1/2 data in NEJM last month

April 8, 2026

Stoke Therapeutics CEO Ian Smith discusses their Dravet syndrome therapy, a novel approach to upregulate a healthy gene, and the path to market.

Already this year Chai Discovery has raised a $130M series B and struck a discovery partnership with Eli Lilly - Co-Founder Jack Dent describes how Chai is using AI to design antibodies

April 6, 2026

Chai Discovery's co-founder explains how their AI platform designs novel antibodies in hours, tackling hard-to-drug targets and partnering with Eli Lilly.

Coya Therapeutics' CEO Arun Swaminathan discusses the company's focus on harnessing T-regs to treat neurodegenerative diseases

March 27, 2026

Coya Therapeutics pioneers a T-reg combination therapy (COIA 302) to halt progression in neurodegenerative diseases like ALS and FTD.

Solid Biosciences CEO Bo Cumo discusses recent DMD data for the company's microdystrophin gene therapy, and explains the development and regulatory steps ahead

March 25, 2026

Solid Bio CEO Bo Cumo on new DMD data for their microdystrophin gene therapy, focusing on delivery, biomarkers, and the FDA approval path.

Apogee Therapeutics' CEO Michael Henderson discusses today's 52 week maintenance data for the company's extended-dose IL-13 inhibitor it atopic dermatitis

March 23, 2026

Apogee's IL-13 drug shows strong 52-week data, targeting atopic dermatitis with a game-changing 3 & 6-month dosing advantage over rivals.

Biotech CEOs discuss the importance of culture, getting through challenging times, their policy wishlist, and how they are proud of the ways our industry gives back

March 20, 2026

Biotech CEOs discuss navigating tough times, the importance of culture, their policy wishlist, and the strength of the Massachusetts ecosystem.

From London: Yellowstone Biosciences is leveraging an Oxford AML patient biobank to develop an HLA Class II platform of T-cell engagers

March 20, 2026

Yellowstone Biosciences is creating first-in-class HLA Class II T-cell engagers, leveraging a unique Oxford biobank from cured AML patients.

From London: iOnctura is developing its allosteric PI3Kδ for uveal melanoma - an indication that has seen progress but still has much unmet need

March 19, 2026

iOnctura's safer PI3Kδ inhibitor, Roganolisib, nears a pivotal overall survival readout in uveal melanoma, addressing a major unmet need.

Checking in with Menlo Ventures' Partner Greg Yap to get his take on the latest trends in AI in healthcare

March 18, 2026

Menlo Ventures' Greg Yap on AI in healthcare: a shift to integrated services, accelerated pharma adoption, and hyper-personalized medicine.

Earli, which raised $105M in two rounds, is developing 'Cancer-Activated Promoters' that are set off by cancer-specific transcription factors and turn tumor cells into therapeutic payload factories

March 17, 2026

Earli uses AI-designed genetic switches to make cancer cells produce their own drugs, turning tumors into on-site therapeutic factories.

Barclays Miami: MannKind CEO Michael Castagna shares an update on the company, including a recent $360M acquisition, and two regulatory reviews at FDA that have decision dates over the coming months

March 11, 2026

MannKind CEO details Afrezza's growth, a $360M acquisition for revenue control, a key partnership update, and a promising IPF pipeline.

Barclays Miami: Barclays' Senior Biotech Analyst Etzer Darout shares his take on biotech and discusses companies he covers that have been in the news

March 11, 2026

Barclays analyst Etzer Darout is bullish on biotech, highlighting Abivax, Corvus, Iovance, Legend & Turns as undervalued with key data readouts.

Barclays Miami: Barclays' Head of Healthcare M&A shares his take on the current environment of dealmaking

March 11, 2026

Barclays' M&A Head sees sustained biotech dealmaking driven by pharma's expiring patents & capital, despite an ebb and flow in deal volume.

Barclays Miami: Recludix believes the time is right in science to drug SH2 domains. The company's lead programs target STAT6 and BTK

March 10, 2026

Recludix is drugging "undruggable" SH2 domains. Their platform targets STAT6 & BTK, offering a new approach to inflammation & immunity.

Barclays Miami: Latigo Bio aims to have a best-in-class Nav1.8 - a new class of medicines for pain that is the biotech sector's answer to the challenges that are presented by opioids

March 10, 2026

Latigo Bio is developing a 'best-in-class' Nav1.8 pain drug, a non-addictive opioid alternative, with distinct programs for acute and chronic pain.

Barclays Miami: enGene is looking to have pivotal data and to file for its non-viral delivered gene therapy for bladder cancer this year

March 10, 2026

enGene discusses its DDX non-viral gene therapy for bladder cancer, with pivotal data updates and plans to file for approval this year.

Quell Tx believes that restoring immune balance rather than entirely depleting immune cells is key for many autoimmune conditions - its CAR-Treg initiated a phase 1/2 in RA & Systemic Sclerosis today

March 3, 2026

Quell Tx pivots its CAR-Treg platform from transplant to autoimmune, betting its 'chill not kill' approach will restore immune balance in RA.

Protagonist Therapeutics has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point

February 20, 2026

Protagonist Therapeutics' execs discuss their oral peptide platform, with two drugs at the FDA, and a pipeline targeting obesity and I&I.

NewLimit is using epigenetic reprogramming to bring cells back to a younger and healthier state, thus tackling age related disease

February 19, 2026

NewLimit is pioneering epigenetic reprogramming to make old cells function like young ones again, developing novel therapies for age-related diseases.

Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity

February 18, 2026

Gordian Biotech is using its high-throughput in vivo screening platform to help Pfizer discover new obesity targets, revolutionizing discovery.

Ocular Therapeutix Chair & CEO Pravin Dugel discusses the result of today's SOL-1 phase 3 superiority trial of AXPAXLI vs EYLEA in wet AMD

February 17, 2026

Ocular Therapeutix's AXPAXLI is the first drug to prove superiority over EYLEA in a landmark Phase 3 trial for wet AMD.

Oxford based Infinitopes raised an additional $15.4M in a second closing of its seed round to bring the total raised to $35.1M. It will have clinical data on its cancer vaccine by the end of the year

February 17, 2026

Infinitopes raises $15.4M, totaling $35.1M for its novel cancer vaccine. Clinical data on its unique immunopeptidomics tech is due by EOY.

Biotech CEOs discuss the state of the industry, what is needed to compete globally, the importance of having a patient-centric approach, and more

February 13, 2026

Biotech CEOs discuss a patient-centric approach, navigating policy and funding, and the need for collaboration to maintain global leadership.

Analyst Thursdays: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened

February 12, 2026

Mizuho's Graig Suvannavejh on key biotech readouts: Ideaya in uveal melanoma, EyePoint in wet AMD, Palvella in rare skin disease & Corvus.

Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist

February 11, 2026

Upstream Bio's verekitug shows strong Ph2 asthma data with 12-week dosing, but market reacts negatively to 24-week results. CEO discusses path to Ph3.

Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib

January 28, 2026

Corvus Pharma CEO discusses soquelitinib's promising atopic dermatitis data, highlighting its novel ITK inhibitor mechanism and durable effects.

SF Healthcare Week: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026

January 17, 2026

Top biotech investor Joe Edelman shares his objective, probability-based investment philosophy, his bullish outlook for 2026, and key holdings.

SF Healthcare Week: Cytokinetics CEO Robert Blum discusses the approval and impending launch of the cardiomyopathy therapy MYQORZO

January 16, 2026

Cytokinetics' CEO discusses the launch of its cardiomyopathy drug MYQORZO, aiming to outcompete BMS with a differentiated, lighter REMS.

SF Healthcare Week: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes

January 16, 2026

Sana Bio's CEO details a potential cure for type 1 diabetes using gene-edited, immune-evasive stem cell-derived islets to end insulin need.

SF Healthcare Week: Neurocrine Biosciences CEO Kyle Gano describes how the company's novel muscarinic agonist portfolio is rooted in novel drug design, with its lead M4 agonist in late-stage trials

January 15, 2026

Neurocrine Biosciences' CEO discusses a strategy of leveraging core biology for new areas like obesity and advancing a selective M4 agonist.

SF Healthcare Week: Recursion's new CEO Najat Khan shares her vision for the company and for AI in biotech

January 15, 2026

Recursion's new CEO Najat Khan shares her vision for leveraging an end-to-end AI platform to deliver differentiated medicines at scale.

SF Healthcare Week: Astellas Pharma CEO Naoki Okamura describes the type of assets the company looks for externally, and covers key internal pipeline assets

January 15, 2026

Astellas CEO outlines its strategy: leveraging a biology-first R&D approach and key assets to drive growth and offset the 2027 Xtandi patent cliff.

SF Healthcare Week: Beam's CEO John Evans shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more

January 12, 2026

Beam Therapeutics' CEO discusses an accelerated FDA pathway for its alpha-1 base editor, a planned BLA filing for its sickle cell therapy, and future platform expansion.

SF Healthcare Week: Vera Therapeutics’ announced this week that the FDA accepted the company’s filing for atacicept, a potential new treatment for IgA Nephropathy

January 12, 2026

Vera Therapeutics' atacicept for IgA Nephropathy gets FDA priority review. With strong Phase 3 data, the company prepares for a July US launch.

Mizuho Senior Biotech Analyst Salim Syed highlights key companies in the news he covers heading into the new year

January 7, 2026

Mizuho's Salim Syed on key biotech catalysts: Eyes on BridgeBio's launch, Cytokinetics' data, Vaxite's macro shift, and Biogen/Arcus value.

William Blair Senior Biotech Analyst Andy Hsieh shares an overview of the obesity space heading into 2026

December 30, 2025

The obesity drug market heats up as Novo's oral Wegovy challenges injectables, but its strict dosing regimen may cede ground to Lilly's orfoglipron.

A deep dive discussion on Abivax with Truist Senior Biotech Analyst Gregory Renza

December 29, 2025

Deep dive on Abivax: Analyst Gregory Renza discusses the upcoming maintenance trial, Obafazimod's risks, and intense M&A speculation.

Create Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."

December 12, 2025

Create Medicines engineers myeloid, T, & NK cells in vivo using a versatile LNP/RNA platform, enabling repeat dosing for solid tumors and beyond.

The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization

December 11, 2025

LabGenius uses ML to design safer, non-intuitive multi-specific antibodies, partnering with Sanofi and advancing its lead Nectin-4 candidate.

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

December 11, 2025

Medra raised $52M to build "physical AI scientists," combining AI reasoning with adaptive robotics to automate and scale scientific discovery.

ASH 2025: Kelonia Therapeutics presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation

December 9, 2025

Colonia Therapeutics' in vivo CAR-T shows deep MRD-negative responses in myeloma without chemo, a potential paradigm shift in cancer therapy.

ASH 2025: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know

December 9, 2025

Corvus Pharma's ITK inhibitor, soquelitinib, shows a remarkable 28-month survival in T-cell lymphoma and is expanding into atopic dermatitis.

ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I

December 8, 2025

Neurix's BTK degrader shows 22.1-month PFS in late-line CLL. CEO discusses strategy for degraders to displace inhibitors across medicine.

ASH 2025: Orca Bio has an April 6th PDUFA date from FDA for its cell therapy product, Orca-T, that aims to solve the problem of treatment-related toxicities that come with stem cell transplants

December 7, 2025

Orca Bio's Orca T therapy aims to replace stem cell transplants for blood cancer, using regulatory T-cells to prevent GVHD. PDUFA is April 6.

Two veterans from MPM have launched a new VC firm that will focus on investing in the I&I space - and it will leverage collaborations with disease specific philanthropies

December 5, 2025

Vi Ventures is launching a new fund for the I&I revolution, leveraging a unique model of partnering with patient foundations to de-risk drug development.

Oxford, UK based Accession Therapeutics raised $40M from existing investors today to further develop its precision viral delivered immunotherapies. The first program induces cancer cells to make PD-L1

December 4, 2025

Accession Therapeutics tackles solid tumors with armed, de-targeted viruses that deliver potent drugs locally, avoiding systemic toxicity.

Jefferies London: Ipsen has done a string of deals over recent years, including acquiring ImCheck last month. CEO David Loew says the company has billions in firepower to do more

November 19, 2025

Ipsen's CEO discusses a growth strategy fueled by neurotoxin innovation, rare disease drug expansion, and over €3B for M&A in oncology.

Jefferies London: Terns' CEO Amy Burroughs previews the company's upcoming ASH presentation for the allosteric BCR::ABL1 inhibitor tern-701 in relapsed/refractory cml

November 19, 2025

Terns Pharmaceuticals' TURNS-701 shows 'best in disease' potential for CML with an unprecedented 64% MMR rate and superior safety profile.

Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and walks us through a few of his firm's top positions

November 19, 2025

Investor Patrick Nosker on biotech's recovery: M&A will continue, driven by pharma needs. Key insights on Xenon, Madrigal, and Alkermes.

Jefferies London: Jefferies Global Chairman of Healthcare Philip Ross discusses the environment for biotech and deals

November 18, 2025

Jefferies' Philip Ross on biotech: M&A thrives on pharma's growth needs, but P&L capacity, not cash, is the real constraint. Outlook is bullish.

Jefferies London: Chief Scientific Officer Tony Wood covers the latest highlights in GSK's pipeline, including oncology, respiratory, and inflammation

November 18, 2025

GSK's CSO Tony Wood outlines their R&D strategy: rebuilding oncology, innovating with long-acting antibodies, and targeted bolt-on acquisitions.

Jefferies London: Protagonist Therapeutics CEO Dinesh Patel responds to takeout speculation and discusses the company's programs and culture of partnering

November 18, 2025

Protagonist Therapeutics' CEO on M&A buzz, lucrative J&J/Takeda deals, and a new oral triple-agonist for the competitive obesity market.

Jefferies London: Jefferies M&A Banker Chris Roop shares his take on the environment for deals in biotech

November 17, 2025

Biopharma M&A is booming, driven by pharma's patent cliffs. Expect more large deals in 2026, fueling capital recycling & industry growth.

Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia

November 13, 2025

Legend Biotech opens a new Philly R&D lab, boosts manufacturing to 10k doses/yr, and celebrates 2nd-line CARVICTI approval in US/EU.

Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.

November 12, 2025

Apogee Therapeutics is developing extended half-life antibodies for I&I diseases, aiming to shift dosing from bi-weekly to quarterly or longer.

Celcuity release what it believes is practice changing breast cancer data with its multi-target PAM inhibitor. Co-Founder & CEO Brian Sullivan describes why he believes the data is so important

November 11, 2025

Cellcuity's gadotolitinib shows historic efficacy in hard-to-treat wild-type HR+/HER2- breast cancer by comprehensively inhibiting the PAM pathway.

Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss

November 11, 2025

Aardvark Therapeutics targets hunger via a novel gut-brain signaling drug, advancing a Phase 3 trial for Prader-Willi syndrome due in '26.

Adaptyx announced $14M in additional seed financing to fund the development of a continuous health monitoring device that aims to track small molecules, electrolytes, hormones, drugs, and proteins

November 10, 2025

Adaptix is creating a wearable biosensor patch for continuous, real-time biochemical monitoring, set to revolutionize clinical care and wellness.

Synthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC

November 8, 2025

Synthakyne's alpha-beta biased IL-2 shows >50% response rate in hard-to-treat lung cancer, promising a safer, more targeted IO therapy.

Menlo Ventures published a report showing that the healthcare industry is the leading adopter of AI - one of the co-authors shares the key takeaways

November 5, 2025

Healthcare's AI boom: A new report reveals surprisingly fast adoption, driven by organic need, with startups outmaneuvering incumbents.

BIO-Europe 2025: Spain based ARTHEx Biotech is a European player in the DM1 space, and believes its microRNA strategy offers a dual benefit that it says is unique to the field

November 4, 2025

Arthex Biotech is developing ATX01 for Myotonic Dystrophy Type 1, using a novel dual-action RNA approach to target both muscle and CNS.

BIO-Europe 2025: Step Pharma has 'followed the genetics' to be the first company to target CTPS1 inhibition for cancer - CEO Andrew Parker walks us through this unique science

November 4, 2025

Step Pharma pioneers a first-in-class CTPS1 inhibitor for oncology, leveraging synthetic lethality for a targeted, safe therapeutic approach.

BIO-Europe 2025: Switzerland based ReproNovo is focused on reproductive health - with two clinical stage assets and three indications it is going after

November 3, 2025

Repro Novo is advancing two Phase 2 assets in reproductive health for male infertility and adenomyosis, funded by a $65M Series A.